Trayanova Lab Publishes Precision Ablation Study in Nature Cardiovascular Research

Trayanova Lab Publishes Precision Ablation Study in Nature Cardiovascular Research The Trayanova Lab at Johns Hopkins University is excited to announce the publication of our latest research in Nature Cardiovascular Research, “Assessing the arrhythmogenic propensity of fibrotic substrate using digital twins to inform a mechanisms-based atrial fibrillation ablation strategy,” (direct Read more…

ADVANCE researchers receive three Johns Hopkins Discovery Awards for innovative research

The three awards will enable ADVANCE researchers to develop deep learning learning methods to understand the recurrence of atrial fibrillation following catheter ablation, artificial intelligence to predict the risk of sudden death in Sarcoidosis, and computational approaches for arrhythmia risk prediction in Arrhythmogenic Right Ventricular Cardiomyopathy. Principal investigator Dr. Natalia Read more…

ablation targets

FDA approves our application for atrial ablation clinical trial

FDA just approved our 160-patient randomized clinical trial to demonstrate the utility of computer simulations driving atrial ablation procedure in patients with persistent atrial fibrillation and fibrosis. The approach is termed OPTIMA (OPtimal Target Identification via Modeling of Arrhythmogenesis). The PIs are Drs. Trayanova, Calkins, and Spraag — clinicians and Read more…

Nature Year in Review 2018: Trayanova on Precision Cardiology

ADVANCE co-director, Natalia Trayanova, PhD, discusses the key developments in precision cardiology in the December 2018 edition of Nature Reviews Cardiology. From a wearable electrocardiogram patch that may reduce the risk of stroke to a personalized virtual heart model that can direct treatment of infarct-related ventricular tachycardia, Trayanova highlights several high-impact advances Read more…